Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?

Journal of Dermatological Treatment

Volumn 26, Issue 2, 2015, Pages 173-177

  Baret, Isabelle ^a   De Haes, Petra ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Polyneuropathy; Refractory cutaneous lupus erythematosus; Thalidomide

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; THALIDOMIDE;

ACUTE CUTANEOUS LUPUS ERYTHEMATOSUS; ACUTE DISEASE; ADULT; AGED; ARTERIAL STENT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONSTIPATION; DISCOID LUPUS ERYTHEMATOSUS; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EVALUATION STUDY; FEMALE; GYNECOMASTIA; HUMAN; HYPOTENSION; IMPOTENCE; LEUKOPENIA; MALE; MIDDLE AGED; MONOTHERAPY; MUSCLE CRAMP; NEUROLOGIC DISEASE; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SKIN LUPUS ERYTHEMATOSUS; STENT THROMBOSIS; TREATMENT RESPONSE; YOUNG ADULT; LUPUS ERYTHEMATOSUS, CUTANEOUS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930789143     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.906036     Document Type: Article

References (28)

1. Rosenbach M, Werth VP. Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther. 2007;20:175-86.
2. Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-73.
3. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options. Part I. J Am Acad Dermatol. 2011;65: e179-93.
4. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options. Part II. J Am Acad Dermatol. 2011; 65:e195-213.
5. Callen JP. Management of 'refractory' skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2005;19: 767-84.
6. Kuhn A, Lehmann P, Ruzicka T. Cutaneous Lupus Erythematosus. Heidelberg: Springer-Verlag, 2004. p 53-8.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revisited criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
8. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108:461-6.
9. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol. 1993; 11:487-93.
10. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol. 1997;36: 353-9.
11. Sato EI, Assis LS, Lourenzi VP, Andrade LE. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras. 1998;44:289-93.
12. Duong DJ, Spiegel T, Moxley RT, Gaspari AA. American experience with low-dose thalidomide therapy of severe cutaneous lupus erythematosus. Arch Dermatol. 1999;135:1079-87.
13. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000;39:218-22.
14. Ordi-Ros J, Cortés F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000;27:1429-33.
15. Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol. 2003;139:50-4.
16. Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118:246-50.
17. Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus. 2005;14:434-9.
18. Briani C, Zara G, Rondinone R, et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004;62:2288-90.
19. Cortés-Hernández J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus prognostic factors of clinical outcome. Br J Dermatol. 2012; 166:616-23.
20. Frankel HC, Sharon VR, Vleugels RA, et al. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol. 2013;52:1407-9.
21. Zara G, Ermani M, Rondinone R, et al. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry. 2008;79:1258-61.
22. Flageul B, Wallach D, Cavelier-Balloy B, et al. Thalidomide and thrombosis. Ann Dermatol Venereol. 2000;127:171-4.
23. Llambrich A, Romero D, Iranzo P, et al. Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide. J Eur Acad Dermatol Venerol. 2007;21:136-7.
24. Piette JC, Sbai A, Francès C. Warning: thalidomide-related trombotic risk potentially concerns patients with lupus. Lupus. 2002;11:67-70.
25. Olivier-Abbal P, Teisseyre A-C, Motastruc J-L. Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database. Med Oncol. 2013;30:733-41.
26. Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145:303-6.
27. Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. 2012;66:571-82.
28. Cortés-Hernández J, A vila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14:R265.